Immunovia

Blood Cancer Screening Adoption Will Drive Long-Term Upside Potential

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

15 Dec 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-65.0%

-10.7%

-65.0%

-10.7%

You can edit this narrative until Dec 16 8:10 PM. Then, changes will post as Updates.

Author's Valuation

SEK 0.7368.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

SEK 0.73

68.5% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

72.38%

Medical Equipment revenue growth rate

6.82%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.99%

Calculation

SEK 7.01m

Earnings '28

83.31x

PE Ratio '28

SEK 583.90m

Market Cap '28

SEK 583.90m

Market Cap '28

672.46m

No. shares '28

SEK 0.87

Share Price '28

SEK 0.87 Share Price '28

Discounted to 2025 @ 5.95% p.a.

SEK 0.73

Fair Value '25